Real-life effectiveness of transitioning from paliperidone palmitate 1-monthly to paliperidone palmitate 3-monthly long-acting injectable formulation

BACKGROUND: Non-adherence to antipsychotics in schizophrenia is associated with an increased risk of psychotic relapse and hospitalization, a risk that is reduced with the use of long-acting injectable (LAI) antipsychotics. Randomized clinical trials (RCTs) have demonstrated the efficacy of paliperi...

Descripción completa

Detalles Bibliográficos
Autores principales: Corbeil, Olivier, Essiambre, Anne-Marie, Béchard, Laurent, Roy, Audrey-Anne, Huot-Lavoie, Maxime, Brodeur, Sébastien, Chandrasena, Ranjith, Thériault, Chantale, Crocker, Candice, Melun, Jean-Pierre, Tibbo, Phil, Demers, Marie-France, Roy, Marc-André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666838/
https://www.ncbi.nlm.nih.gov/pubmed/36405400
http://dx.doi.org/10.1177/20451253221136021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666838/
https://www.ncbi.nlm.nih.gov/pubmed/36405400
http://dx.doi.org/10.1177/20451253221136021

Ejemplares similares